Nifty
Sensex
:
:
10906.95
36386.61
1.75 (0.02%)
12.53 (0.03%)

Pharmaceuticals & Drugs

Rating :
50/99

BSE: 524715 | NSE: SUNPHARMA

390.75
-35.80 (-8.39%)
18-Jan-2019 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  424.05
  •  424.10
  •  370.20
  •  426.55
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  82906214
  •  323956.03
  •  679.30
  •  370.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 102,487.31
  • 42.04
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 102,943.20
  • 0.47%
  • 2.50

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.38%
  • 4.10%
  • 6.72%
  • FII
  • DII
  • Others
  • 0.84%
  • 15.64%
  • 18.32%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 19.98
  • 10.44
  • -2.05

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.50
  • -4.48
  • -7.47

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 1.87
  • -6.99
  • -21.63

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 31.31
  • 40.72
  • 39.25

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.67
  • 5.67
  • 4.26

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.60
  • 19.04
  • 17.44

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Dec 17
Dec 16
Var%
Net Sales
6,937.63
6,650.34
4.32%
7,224.17
6,208.79
16.35%
6,977.10
7,136.96
-2.24%
6,653.23
7,925.11
-16.05%
Expenses
5,406.42
5,274.73
2.50%
5,617.47
5,113.14
9.86%
5,293.61
5,589.48
-5.29%
5,199.85
5,471.98
-4.97%
EBITDA
1,531.21
1,375.61
11.31%
1,606.70
1,095.65
46.64%
1,683.49
1,547.48
8.79%
1,453.38
2,453.13
-40.75%
EBIDTM
22.07%
20.68%
22.24%
17.65%
24.13%
21.68%
21.84%
30.95%
Other Income
351.15
254.84
37.79%
199.75
151.98
31.43%
302.75
224.50
34.86%
129.19
122.15
5.76%
Interest
129.53
157.44
-17.73%
130.90
109.42
19.63%
155.38
44.99
245.37%
95.33
166.47
-42.73%
Depreciation
426.51
358.65
18.92%
401.64
346.63
15.87%
455.24
338.17
34.62%
339.32
306.80
10.60%
PBT
111.94
1,114.36
-89.95%
1,273.91
-158.92
-
1,375.62
1,388.82
-0.95%
1,147.92
2,102.01
-45.39%
Tax
218.91
111.40
96.51%
163.86
161.78
1.29%
-176.69
44.30
-
748.70
372.92
100.77%
PAT
-106.97
1,002.96
-
1,110.05
-320.70
-
1,552.31
1,344.52
15.45%
399.22
1,729.09
-76.91%
PATM
-1.54%
15.08%
15.37%
-5.17%
22.25%
18.84%
6.00%
21.82%
EPS
-0.91
3.80
-
4.09
-1.77
-
5.46
5.10
7.06%
1.52
6.13
-75.20%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
27,792.13
26,415.54
31,308.14
28,108.61
27,392.01
16,080.36
11,299.86
8,019.49
5,727.90
4,007.45
4,272.30
Net Sales Growth
-0.46%
-15.63%
11.38%
2.62%
70.34%
42.31%
40.90%
40.01%
42.93%
-6.20%
 
Cost Of Goods Sold
7,734.32
7,318.73
8,164.20
6,170.19
6,732.84
2,777.68
2,076.36
1,647.61
1,460.40
1,098.45
848.40
Gross Profit
20,057.81
19,096.81
23,143.94
21,938.42
20,659.17
13,302.68
9,223.50
6,371.88
4,267.50
2,909.00
3,423.90
GP Margin
72.17%
72.29%
73.92%
78.05%
75.42%
82.73%
81.62%
79.45%
74.50%
72.59%
80.14%
Total Expenditure
21,517.35
20,880.73
21,625.92
19,950.29
19,615.54
9,120.95
6,437.76
4,836.43
3,785.07
2,644.63
2,408.35
Power & Fuel Cost
-
559.97
525.09
545.44
560.77
232.41
187.10
145.65
96.78
91.92
97.77
% Of Sales
-
2.12%
1.68%
1.94%
2.05%
1.45%
1.66%
1.82%
1.69%
2.29%
2.29%
Employee Cost
-
5,367.05
4,902.30
4,772.31
4,502.64
2,074.44
1,534.53
1,187.73
818.95
396.84
336.65
% Of Sales
-
20.32%
15.66%
16.98%
16.44%
12.90%
13.58%
14.81%
14.30%
9.90%
7.88%
Manufacturing Exp.
-
1,401.09
1,293.98
1,418.59
1,433.89
815.49
618.43
462.65
338.40
398.53
464.82
% Of Sales
-
5.30%
4.13%
5.05%
5.23%
5.07%
5.47%
5.77%
5.91%
9.94%
10.88%
General & Admin Exp.
-
3,288.76
3,113.67
2,956.85
2,894.97
978.48
793.38
629.48
480.66
215.47
144.49
% Of Sales
-
12.45%
9.95%
10.52%
10.57%
6.08%
7.02%
7.85%
8.39%
5.38%
3.38%
Selling & Distn. Exp.
-
1,864.55
2,520.64
2,262.35
2,236.40
1,394.78
763.01
516.55
372.14
290.33
388.60
% Of Sales
-
7.06%
8.05%
8.05%
8.16%
8.67%
6.75%
6.44%
6.50%
7.24%
9.10%
Miscellaneous Exp.
-
1,080.58
1,106.04
1,824.56
1,254.03
847.67
464.95
246.76
217.74
153.09
388.60
% Of Sales
-
4.09%
3.53%
6.49%
4.58%
5.27%
4.11%
3.08%
3.80%
3.82%
2.99%
EBITDA
6,274.78
5,534.81
9,682.22
8,158.32
7,776.47
6,959.41
4,862.10
3,183.06
1,942.83
1,362.82
1,863.95
EBITDA Margin
22.58%
20.95%
30.93%
29.02%
28.39%
43.28%
43.03%
39.69%
33.92%
34.01%
43.63%
Other Income
982.84
912.08
1,030.20
658.25
637.89
592.59
422.23
492.77
375.08
211.48
214.36
Interest
511.14
517.57
399.80
523.24
578.99
44.19
43.16
28.20
73.88
6.15
5.85
Depreciation
1,622.71
1,499.84
1,264.75
1,037.53
1,194.72
409.23
336.17
291.16
204.85
153.31
123.29
PBT
3,909.39
4,429.48
9,047.87
7,255.80
6,640.65
7,098.58
4,905.00
3,356.47
2,039.18
1,414.84
1,949.17
Tax
954.78
845.19
1,211.57
913.77
914.69
702.17
845.55
313.19
128.58
67.86
71.16
Tax Rate
24.42%
24.29%
13.39%
13.91%
14.29%
15.33%
19.57%
9.33%
6.31%
4.80%
3.65%
PAT
2,954.61
2,186.99
6,954.44
4,544.26
4,551.94
3,141.47
2,989.59
2,657.80
1,819.29
1,351.08
1,817.73
PAT before Minority Interest
2,461.27
2,633.79
7,836.30
5,656.86
5,488.21
3,879.00
3,475.87
3,043.28
1,910.60
1,346.98
1,878.01
Minority Interest
-493.34
-446.80
-881.86
-1,112.60
-936.27
-737.53
-486.28
-385.48
-91.31
4.10
-60.28
PAT Margin
10.63%
8.28%
22.21%
16.17%
16.62%
19.54%
26.46%
33.14%
31.76%
33.71%
42.55%
PAT Growth
-21.33%
-68.55%
53.04%
-0.17%
44.90%
5.08%
12.48%
46.09%
34.65%
-25.67%
 
Unadjusted EPS
10.16
9.00
29.00
18.90
18.90
15.20
14.40
25.70
17.50
13.00
87.80

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
38,100.56
36,639.67
32,982.48
25,638.09
18,524.95
14,989.73
12,235.78
9,483.32
7,828.91
7,044.92
Share Capital
239.93
239.93
240.66
207.12
207.12
103.56
103.56
103.56
103.56
103.56
Total Reserves
37,860.63
36,397.10
32,736.26
25,374.38
18,317.83
14,886.17
12,132.22
9,379.76
7,725.35
6,941.36
Non-Current Liabilities
259.98
599.87
2,169.59
2,335.46
1,748.41
199.02
-225.23
-188.27
82.11
110.99
Secured Loans
217.69
185.59
7.73
40.69
43.76
41.90
49.65
4.38
100.35
36.38
Unsecured Loans
1,554.40
1,250.49
3,102.57
1,327.73
4.91
73.36
105.77
152.90
70.80
142.51
Long Term Provisions
404.46
1,211.11
1,895.86
2,532.34
2,601.62
787.06
138.73
13.00
0.00
0.00
Current Liabilities
19,864.32
17,887.02
13,143.96
16,146.81
5,989.59
2,841.25
2,618.49
1,730.88
757.92
719.81
Trade Payables
4,766.20
4,395.39
3,582.92
3,286.54
1,328.26
1,057.99
992.72
645.38
319.44
254.34
Other Current Liabilities
1,875.93
2,673.68
1,134.27
2,279.59
260.41
218.65
363.66
362.42
90.07
122.37
Short Term Borrowings
7,979.70
6,654.92
5,206.12
6,227.92
2,440.34
82.95
109.57
207.78
0.00
0.00
Short Term Provisions
5,242.49
4,163.03
3,220.65
4,352.76
1,960.58
1,481.66
1,152.54
515.30
348.41
343.10
Total Liabilities
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08
15,790.49
11,873.08
8,862.13
8,072.76
Net Block
18,852.65
17,675.17
15,872.25
12,682.47
6,817.28
5,647.47
3,951.35
3,293.35
1,938.82
1,787.88
Gross Block
26,948.81
24,466.42
22,180.41
20,406.89
10,485.12
8,709.22
6,448.66
5,319.27
2,740.07
2,472.95
Accumulated Depreciation
8,096.16
6,791.25
6,308.16
7,724.42
3,667.84
3,061.75
2,497.31
2,025.92
801.25
685.07
Non Current Assets
30,473.12
25,963.77
22,439.98
18,055.80
9,497.56
8,161.89
5,496.96
4,279.84
3,567.95
3,004.28
Capital Work in Progress
2,465.16
2,801.38
2,175.45
2,038.61
841.54
562.61
344.65
235.46
144.82
157.10
Non Current Investment
3,052.25
961.00
1,116.07
598.87
787.56
1,106.35
588.96
346.01
1,484.31
1,059.30
Long Term Loans & Adv.
6,052.97
3,844.04
2,322.87
2,631.91
1,016.98
802.56
593.29
377.27
0.00
0.00
Other Non Current Assets
50.09
682.18
953.34
103.94
34.20
42.90
18.71
27.75
0.00
0.00
Current Assets
31,635.90
32,953.65
29,941.30
28,915.75
18,686.46
11,503.03
10,293.37
7,593.05
5,294.18
5,068.48
Current Investments
4,090.62
230.88
713.81
2,117.43
1,998.46
1,305.22
1,623.91
1,883.75
1,682.07
800.19
Inventories
6,880.69
6,832.81
6,422.54
5,667.99
3,123.01
2,577.76
2,086.98
1,489.48
1,073.85
975.70
Sundry Debtors
7,815.28
7,202.61
6,775.66
5,106.13
2,200.42
2,412.23
2,078.74
1,104.87
1,174.77
881.09
Cash & Bank
9,929.38
15,140.84
13,181.65
10,998.04
7,590.15
4,058.71
3,367.19
2,204.63
508.89
1,669.03
Other Current Assets
2,919.93
718.25
530.51
3,105.64
3,774.42
1,149.11
1,136.55
910.32
854.60
742.47
Short Term Loans & Adv.
2,028.62
2,828.26
2,317.13
1,920.52
1,093.74
952.93
976.71
784.37
835.09
685.21
Net Current Assets
11,771.58
15,066.63
16,797.34
12,768.94
12,696.87
8,661.78
7,674.88
5,862.17
4,536.26
4,348.67
Total Assets
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08
15,790.49
11,873.08
8,862.13
8,072.76

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
3,907.15
7,082.21
6,685.86
5,615.74
3,959.20
3,356.58
2,234.46
2,283.10
781.13
2,164.89
PBT
3,478.98
9,047.87
6,570.63
6,402.90
4,581.17
4,314.89
3,355.36
2,035.95
1,414.84
1,949.17
Adjustment
1,382.22
500.67
1,856.92
773.61
-40.15
160.00
111.12
-171.18
-23.60
381.77
Changes in Working Capital
-212.31
-409.21
246.77
179.59
207.10
-44.83
-1,005.25
487.65
-435.63
2.94
Cash after chg. in Working capital
4,648.89
9,139.33
8,674.32
7,356.10
4,748.12
4,430.06
2,461.23
2,352.42
955.61
2,333.88
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-741.74
-2,057.12
-1,988.46
-1,740.36
-788.92
-1,073.48
-226.77
-69.32
-174.48
-168.99
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-3,370.81
-4,221.60
-4,371.59
-2,865.74
-2,366.76
-2,635.05
-862.71
-1,847.71
-213.74
-1,773.02
Net Fixed Assets
-714.76
-1,217.15
2,214.23
-4,631.67
-380.81
-341.28
-267.49
-212.50
-114.06
-169.39
Net Investments
978.04
3,038.39
3,504.47
-18,860.43
-2,698.19
120.24
-836.36
450.27
-1,357.10
-751.47
Others
-3,634.09
-6,042.84
-10,090.29
20,626.36
712.24
-2,414.01
241.14
-2,085.48
1,257.42
-852.16
Cash from Financing Activity
-1,539.26
-2,285.39
-1,888.53
-1,186.53
506.57
-664.99
-544.39
-804.19
-346.43
-266.62
Net Cash Inflow / Outflow
-1,002.92
575.22
425.74
1,563.47
2,099.01
56.54
827.36
-368.80
220.96
125.25
Opening Cash & Equivalents
8,642.36
8,031.69
7,183.49
4,358.70
2,069.11
1,752.67
810.49
633.87
451.24
325.99
Closing Cash & Equivalent
7,906.45
8,642.36
8,031.69
7,285.56
4,358.70
2,069.11
1,752.67
810.49
672.20
451.24

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
158.80
152.70
137.03
123.49
89.44
72.37
59.08
45.79
37.80
34.01
ROA
4.35%
14.08%
11.39%
14.60%
16.21%
19.61%
22.00%
18.43%
15.91%
26.75%
ROE
7.05%
22.51%
19.32%
24.89%
23.15%
25.53%
28.02%
22.07%
18.11%
31.21%
ROCE
8.42%
21.48%
18.64%
25.06%
25.46%
31.39%
30.13%
23.60%
18.67%
31.64%
Fixed Asset Turnover
1.03
1.35
1.34
1.79
1.70
1.51
1.38
1.44
1.57
2.06
Receivable days
103.47
80.78
76.12
48.20
51.72
71.46
71.49
71.57
91.85
95.89
Inventory Days
94.48
76.61
77.46
57.99
63.92
74.22
80.31
80.48
91.57
72.94
Payable days
92.31
77.57
75.24
52.05
56.33
65.15
64.51
51.06
42.23
38.20
Cash Conversion Cycle
105.64
79.82
78.34
54.14
59.31
80.53
87.29
100.98
141.19
130.62
Total Debt/Equity
0.27
0.27
0.26
0.35
0.14
0.02
0.03
0.04
0.02
0.03
Interest Cover
7.72
23.63
13.56
12.06
104.67
101.13
120.02
28.60
231.06
334.19

News Update:


  • Sun Pharma’s arm recalling 13,918 cartons of Vecuronium Bromide for Injection from US
    10th Jan 2019, 09:52 AM

    The Vecuronium Bromide for Injection has been found to contain particulate matter identified as glass

    Read More
  • Sun Pharma’s arm completes acquisition of Pola Pharma
    3rd Jan 2019, 16:31 PM

    The company’s arm has completed the acquisition of 100% shares of Pola Pharma Inc., Japan

    Read More
  • Sun Pharma’s arm gets preliminary injunctive relief Prohibiting Biofrontera
    27th Dec 2018, 09:01 AM

    The company’s arm has been granted preliminary injunctive relief by a federal district court

    Read More
  • Sun Pharma's arm receives USFDA’s approval for ELEPSIA XR 1000mg, 1500mg
    21st Dec 2018, 16:06 PM

    This product was filed from SPIL’s Halol facility in the state of Gujarat

    Read More
  • Sun Pharmaceutical gets US FDA approval for Generic Ganirelix Acetate Injection
    3rd Dec 2018, 09:33 AM

    The generic version is therapeutic equivalent to Organon’s Ganirelix Acetate Injection, 250 mcg/0.5 mL

    Read More
  • Sun Pharma settles Modafinil antitrust litigation matter in US with certain plaintiffs
    27th Nov 2018, 11:07 AM

    The settlements extend to all claims brought by the Direct Purchaser Plaintiffs

    Read More
  • Sun Pharma’s arm to acquire 100% stake in Pola Pharma
    26th Nov 2018, 16:07 PM

    This acquisition would give commercial presence in the dermatology segment in Japan

    Read More
  • Sun Pharma reports consolidated net loss of Rs 219 crore in Q2
    14th Nov 2018, 10:26 AM

    Total consolidated income of the company increased by 5.56% at Rs 7,288.78 crore for Q2FY19

    Read More
  • Sun Pharma Inds. - Quarterly Results
    13th Nov 2018, 15:45 PM

    Read More
  • Sun Pharma comes up with psoriasis treatment drug ‘ILUMYA’ in US
    24th Oct 2018, 09:40 AM

    ILUMYA injections are administered by a healthcare provider every 12 weeks

    Read More
  • Sun Pharmaceutical to invest additional Rs 200 crore in Assam plant
    15th Oct 2018, 12:09 PM

    The company has inaugurated a new production line at its facility in Palashbari

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.